Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Flamel Technologies (AVDL) Share Price
News stories about Flamel Technologies (NASDAQ:AVDL) have trended somewhat positive recently, according to Accern Sentiment. The research group identifies positive and negative media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Flamel Technologies earned a news sentiment score of 0.06 on Accern’s scale. Accern also gave news articles about the company an impact score of 47.6113275539568 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the news articles that may have effected Accern Sentiment Analysis’s rankings:
- Flamel Technologies S.A. (NASDAQ:AVDL) Forecasted to Post Q3 2017 Earnings of ($0.03) Per Share (americanbankingnews.com)
- Avadel Pharmaceuticals Reports Second Quarter 2017 Results (finance.yahoo.com)
- Avadel posts 2Q profit (finance.yahoo.com)
- Flamel Technologies S.A. (NASDAQ:AVDL) Releases Quarterly Earnings Results (americanbankingnews.com)
- Flamel Technologies S.A. (AVDL) Releases FY17 Earnings Guidance (americanbankingnews.com)
Several equities analysts recently issued reports on the stock. Zacks Investment Research cut shares of Flamel Technologies from a “strong-buy” rating to a “hold” rating in a research report on Friday, May 12th. Roth Capital set a $15.00 price objective on shares of Flamel Technologies and gave the stock a “buy” rating in a research note on Wednesday. One research analyst has rated the stock with a sell rating and three have assigned a buy rating to the stock. Flamel Technologies presently has an average rating of “Buy” and an average price target of $14.75.
Shares of Flamel Technologies (NASDAQ:AVDL) traded up 3.23% during mid-day trading on Friday, reaching $8.62. 171,393 shares of the company’s stock were exchanged. The company’s 50-day moving average price is $10.09 and its 200-day moving average price is $9.97. The company has a market capitalization of $345.52 million, a PE ratio of 9.10 and a beta of 1.37. Flamel Technologies has a one year low of $8.14 and a one year high of $15.45.
Flamel Technologies (NASDAQ:AVDL) last issued its quarterly earnings results on Tuesday, August 8th. The company reported $0.19 EPS for the quarter, topping the consensus estimate of $0.05 by $0.14. The company had revenue of $46.30 million during the quarter, compared to analyst estimates of $45.17 million. Flamel Technologies had a net margin of 21.13% and a return on equity of 29.86%. The company’s revenue was up 19.0% on a year-over-year basis. On average, equities analysts expect that Flamel Technologies will post $0.54 earnings per share for the current year.
In other Flamel Technologies news, major shareholder Healthcare Master Fun Broadfin sold 261,000 shares of the company’s stock in a transaction dated Friday, June 23rd. The shares were sold at an average price of $10.68, for a total value of $2,787,480.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Guillaume Cerutti sold 26,560 shares of the company’s stock in a transaction dated Thursday, June 15th. The shares were sold at an average price of $10.46, for a total transaction of $277,817.60. Following the completion of the transaction, the director now directly owns 23,440 shares in the company, valued at approximately $245,182.40. The disclosure for this sale can be found here. 5.07% of the stock is owned by corporate insiders.
About Flamel Technologies
Flamel Technologies SA is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its polymer based technology. The Company has a balanced business model consisting of an Unapproved Marketed Drugs (UMDs) business with over two approved products in the United States, Bloxiverz (neostigmine methylsulfate injection) and Vazculep (phenylephrine hydrochloride injection) that are marketed; a branded pediatric business, and a branded business, focusing on the development of products utilizing Flamel’s drug delivery platforms.
Receive News & Ratings for Flamel Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flamel Technologies S.A. and related companies with MarketBeat.com's FREE daily email newsletter.